Pacer Advisors Inc. Sells 299,354 Shares of IQVIA Holdings Inc. $IQV

Pacer Advisors Inc. decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 29.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 728,498 shares of the medical research company’s stock after selling 299,354 shares during the quarter. Pacer Advisors Inc. owned about 0.43% of IQVIA worth $138,371,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Asset Dedication LLC boosted its position in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after purchasing an additional 168 shares in the last quarter. Trust Co. of Toledo NA OH bought a new position in IQVIA during the second quarter worth about $39,000. J.Safra Asset Management Corp lifted its holdings in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after acquiring an additional 169 shares in the last quarter. Rothschild Investment LLC grew its stake in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares during the period. Finally, NewSquare Capital LLC increased its holdings in shares of IQVIA by 185.3% in the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after acquiring an additional 189 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $226.00 on Friday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $234.29. The firm has a fifty day simple moving average of $220.73 and a 200 day simple moving average of $194.34. The stock has a market capitalization of $38.49 billion, a price-to-earnings ratio of 31.00, a PEG ratio of 2.50 and a beta of 1.37.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. IQVIA’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on IQV shares. Truist Financial reiterated a “buy” rating and issued a $265.00 price objective (up from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Stifel Nicolaus upped their price target on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Morgan Stanley raised their price objective on shares of IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a report on Monday, December 1st. BMO Capital Markets initiated coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, Evercore ISI increased their target price on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $243.19.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.